Can-Fite BioPharma Ltd. (CANF) Earnings History
Annual and quarterly earnings data from 2011 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -1206.2% | -1169.1% |
| 2023 | 100.0% | -1103.0% | -1027.5% |
| 2022 | 100.0% | -1246.4% | -1255.9% |
| 2021 | 100.0% | -1505.5% | -1476.6% |
| 2020 | 100.0% | -1853.1% | -1892.9% |
Download Data
Export CANF earnings history in CSV or JSON format
Free sign-in required to download data
Can-Fite BioPharma Ltd. (CANF) Earnings Overview
As of February 28, 2026, Can-Fite BioPharma Ltd. (CANF) reported trailing twelve-month net income of -$9M, reflecting +0.4% year-over-year growth. The company earned $-0.77 per diluted share over the past four quarters, with a net profit margin of -11.7%.
Looking at the long-term picture, CANF's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2015.
Can-Fite BioPharma Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including ARGX ($923M net income, 0.4% margin), AKTX (-$16M net income), ABVX (-$332M net income, -16.3% margin), CANF has room to improve margins relative to the peer group. Compare CANF vs ARGX →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$8M | -3.2% | -$8M | $-1.08 | -1169.1% | -1206.2% |
| 2023 | -$8M | +25.0% | -$8M | $-1.80 | -1027.5% | -1103.0% |
| 2022 | -$10M | +19.2% | -$10M | $-3.75 | -1255.9% | -1246.4% |
| 2021 | -$13M | +12.8% | -$13M | $-8.25 | -1476.6% | -1505.5% |
| 2020 | -$14M | -14.4% | -$14M | $-12.69 | -1892.9% | -1853.1% |
| 2019 | -$13M | -92.1% | -$12M | $-45.00 | -621.3% | -590.9% |
| 2018 | -$7M | -32.2% | -$5M | $-51.00 | -172.0% | -141.7% |
| 2017 | -$5M | +28.0% | -$7M | $-57.00 | -588.2% | -873.1% |
| 2016 | -$7M | -43.8% | -$9M | $-90.00 | -4069.3% | -5093.7% |
| 2015 | -$5M | +21.4% | -$6M | $-81.00 | -2912.3% | -3894.6% |
See CANF's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CANF Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CANF vs AGIO
See how CANF stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CANF growing earnings?
CANF EPS of $-0.77 reflects slowing growth at +0.4%, below the 5-year CAGR of N/A. TTM net income is $-9M. Expansion rate has moderated.
What are CANF's profit margins?
Can-Fite BioPharma Ltd. net margin is -11.7%, with operating margin at -12.1%. Below-average margins reflect competitive or cost pressures.
How consistent are CANF's earnings?
CANF earnings data spans 2011-2024. The current earnings trend is +0.4% YoY. Historical data enables comparison across business cycles.